Why do so many clinical trials of therapies for Alzheimer's disease fail?
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several attempts at targeting Aβ amyloid in AD have failed [288,289].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [288]
In the citing paper
“Given the fact that longer trial durations increase the probability of detecting a significant effect but at the same time increase tremendously the costs, the proposed solution seems to be the use of clinical trial simulators.28”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [28]
In the citing paper
“A novel approach to the problem seems more technical and mathematical than biological and suggests that the selected trials’ clinical endpoint may be extremely premature, and additionally, the variability in diagnostic markers and end points may result in inaccurate diagnosis of patients’ disease state and is finally a definite source of errors.28”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [28]
In the citing paper
“No new drug has been approved by FDA for AD since 2003 and there are no approved DMTs for AD, despite many long and expensive trials.22,28”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [28]
Citations
Cites
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Morris, J. C., Weintraub, S., Chui, H. C., Cummings, J., DeCarli, C., Ferris, S., Foster, N. L., Galasko, D., Graff-Radford, N., Peskind, E. R., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213865.09806.92 · Cited by 950
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0189-7 · Cited by 304
Holford, N. H. G., Kimko, H. C., Monteleone, J. P. R., & Peck, C. C. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.209 · Cited by 289
Why has therapy development for dementia failed in the last two decades?
Gauthier, S., Albert, M., Fox, N., Goedert, M., Kivipelto, M., Mestre‐Ferrandiz, J., & Middleton, L. T. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.12.003 · Cited by 238
Endpoints for trials in Alzheimer's disease: a European task force consensus
Vellas, B. J., Andrieu, S., Sampaio, C., Coley, N., & Wilcock, G. K. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70087-5 · Cited by 165
Cited by
Religious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260
“Estimatessuggestthatstud-iestoslowcognitivedeclineinasymptomaticpersons mayneedtobemuchlongerthaniscurrentlybeing done[448].”
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330
Metadata
- Authors
- Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Anderson, Roy M
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 390
- Issue
- 10110
- Pages
- 2327-2329
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2769095960
- Cited by
- 228
- References
- 17
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 26 · 2022: 40 · 2021: 25 · 2020: 47 · 2019: 25 · 2018: 13
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U01AG016976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- Alzheimer's disease, clinical trial failure, trial design, statistical power, surrogate endpoints, composite endpoints, mild cognitive impairment, dementia progression, amyloid-beta, tau pathology
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Clinical Trials as Topic, Female, Humans, Male, Antipsychotic Agents, Treatment Failure, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Why do so many clinical trials of therapies for Alzheimer's disease fail? https://app.cochat.ai/papers/10.1016/s0140-6736(17)32399-1
- The paper
- Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017). Why do so many clinical trials of therapies for Alzheimer's disease fail? The Lancet. https://doi.org/10.1016/s0140-6736(17)32399-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.